Neuraxis (NRXS) Cash from Operations (2022 - 2025)
Neuraxis (NRXS) posted Cash from Operations of 1934159.0 for Q4 2025, down 35.49% sequentially from 1427539.0 in Q3 2025, and down 10.01% YoY from 2149303.67 in Q4 2024.
Neuraxis (NRXS) Cash from Operations (2022 - 2025) Analysis & Trends
Neuraxis has reported Cash from Operations for 4 years, with the latest figure at 1934159.0 in Q4 2025.
- Quarterly Cash from Operations fell 10.01% year-over-year to 1934159.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 6432843.0 (down 5.49% YoY) and the FY2025 annual result came in at 6432843.0, down 5.49% from the prior year.
- Cash from Operations declined to 1934159.0 in Q4 2025 per NRXS's latest filing, from 1427539.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 214315.0 in Q4 2022 and troughed at 2816282.0 in Q3 2023.
- A 4-year average of 1453656.71 and a median of 1447514.5 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations tumbled 1126.96% in 2023, then jumped 50.54% in 2024.
- Over 4 years, Cash from Operations stood at 214315.0 in 2022, then sank by 1126.96% to 2629559.0 in 2023, then surged by 33.14% to 1758167.0 in 2024, then dropped by 10.01% to 1934159.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 1934159.0, 1427539.0, and 1467490.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.93 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | -1.47 Mn |
| Jun 30, 2025 | -1.47 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -1.76 Mn |
| Dec 31, 2024 | -1.76 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | -1.62 Mn |
| Jun 30, 2024 | -1.62 Mn |
| Mar 31, 2024 | -1.33 Mn |
| Mar 31, 2024 | -1.33 Mn |
| Dec 31, 2023 | -2.63 Mn |
| Dec 31, 2023 | -2.63 Mn |
| Sep 30, 2023 | -2.82 Mn |
| Sep 30, 2023 | -2.82 Mn |